Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Govt to amend norms to...

    Govt to amend norms to empower NPPA to fix prices of 350 drugs

    Written by supriya kashyap kashyap Published On 2017-02-13T11:12:17+05:30  |  Updated On 13 Feb 2017 11:12 AM IST
    Govt to amend norms to empower NPPA to fix prices of 350 drugs

    Bengaluru : The government said it will soon amend norms to empower National Pharmaceutical Pricing Authority (NPPA) to regulate about 350 medicines and ensure they are sold at affordable rates.


    At present, NPPA is not able to regulate 350 medicines, which are under the National List of Essential Medicines (NLEM), in the absence of market data. Therefore, the authority needs to be empowered by amending the Drugs Prices Control Order (DPCO) for accessing the data.


    "It (amendments) will be done soon. Whatever required to empower NPPA will be done. It will be an independent authority vested with all powers," Union Chemicals and Fertilisers Minister Ananth Kumar said on the sidelines of an international event 'India Pharma 2017' here.


    The price regulator will ensure that all medicines are regulated and are available at affordable rates to the public, he said.


    Last year in August, the Minister had said that the DPCO will be amended in 15 days to enable NPPA regulate about 350 medicines. But the amendments have not yet been done.


    Kumar said that much progress has been made to ensure medicines are available at affordable rates to people.


    In last four-six months, about 1,450 medicines have been brought under the Drugs (Prices Control) Order, (DPCO) 2013 resulting in a saving of about Rs 5,000 crore to consumers, he said.


    "Before 2014, prices of not 30-40 per cent medicines were controlled. For the first time, 1,450 medicines are brought under DPCO very successfully in last 4-6 months," he said.


    Stating that India has potential to be 'pharmacy' of the world, Kumar said the government is promoting in a big way domestic manufacturing of bulk drugs active pharmaceutical ingredients (APIs) and medical devices.


    He said that five med-tech zones and six pharma parks are being set up, while 100 per cent FDI has been allowed including in brown-field projects.


    Efforts are being made to reduce the country's dependence on import of medical devices, he said.


    The Indian pharma industry has potential to reach USD 55 billion in the next couple of years from the current USD 33 billion, he added.

    Active Pharmaceutical IngredientAnanth KumarAPIDPCODrugs Prices Control OrderFDINational List of Essential MedicinesNational Pharmaceutical Pricing AuthorityNLEMNPPA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok